Navigation Links
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Date:7/28/2008

million. Additional financial details will be provided on the August 5, 2008 earning conference call.

Conference Call

The company has scheduled a conference call for today, Monday, July 28, 2008, at 10:30 AM ET to discuss the FDA's response. Investors can call 1-866-202-3109 (domestic) and 1-617-213-8844 (international) prior to the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. A replay of the call will be available Monday, July 28, 2008, at 12:30 PM ET and will be accessible until Monday, August 4, 2008, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 48122809.

The conference call will be broadcast simultaneously on the company's Web site, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, and install any necessary software. The call will also be archived on the Vanda Web site for a period of 30 days, through August 27, 2008.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company with a focus on the development and commercialization of clinical-stage product candidates for central nervous system disorders. In addition to iloperidone, Vanda is developing tasimelteon (VEC- 162), a compound for the treatment of sleep and mood disorders which is currently in Phase III development for sleep disorders. Vanda's third product candidate in clinical development, VSF-173, is currently in Phase II development for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Cautionary Note Regarding Forward-Looking Statements

Various statements in this release
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
2. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
3. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
4. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
5. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
6. Vanda Pharmaceuticals to Present at Natixis Bleichroeders Hidden Gems Conference
7. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
8. New Natural Product from Zurich Pharmaceuticals Downs Appetite
9. AUDIO from Medialink and Duramed Pharmaceuticals: Not Your Mothers Menopause
10. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
11. Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...e University College of Medicine research team led...layer of regulation in the cell division cycle, wh...ay cancer begins. , Wang, an assistant professor..., said the findings will lead to an improved abili... of new drugs that kill cancer cells by inhibiting...
(Date:11/21/2008)...ewswire/ -- The Generic,Pharmaceutical Associatio...om,GPhA President and CEO Kathleen Jaeger regardi...on "Emerging Health Care Competition and Consumer ...onducting this roundtable demonstrates the,growin...ess to safe and,affordable biogenerics sooner rat...
(Date:11/21/2008)...USNewswire/ -- New research at West Virginia Univ... tobacco product aimed at young adults is catching...ds, Camel Snus - touted as a socially acceptable w...gh levels of nicotine. , , "Camel Snus cont..." said Bruce Adkins of the state Division of Tobac...
(Date:11/21/2008)...re-FirstCall/ -- Today, prescription drugs are the... 88 percent of patients suffering chronic conditio...onic condition account for 96 percent of all presc...l costs. A proprietary new pharmacy model develop.... (NYSE: MHS ) significantly reduces critical ga...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6
...h officials are all set to oil the wheels of retai...opose new regulations to allow for the operation o...lso encourage not-for-profit hospitals, community ... basic medical services. The proposed changes wer...
...ntified the first gene that is linked to Restless ...er that affects millions of people worldwide . RL...ering need to move the legs and is also a major ca...sleep disturbance. We now have concrete evidence t...
...from heart disease among younger Britons is slowin... research published ahead of print in the journal ...nary artery heart disease in England and Wales bet...gures.They used the data to calculate heart diseas...
...f more than a thousand prisoners has failed to sol...e and prisoner rehabilitation programmes, said th...niversary of the Ministry of Justices introduction...lleviate the overcrowding crisis in English and We...
Other Medicine News:Health News:Retail Health Clinics Start Shop 2Health News:Gene Linked With Restless Leg Syndrome Spotted Out 2Health News:Disquieting Slow Down in Heart Disease Deaths Among Under 55s 2Health News:Prison Healthcare Continues to Fail Despite Emergency Measures, Warns BMA 2
(Date:11/19/2008)...istical significance , , ISELIN, N.J., Nov.... (Nasdaq: PARS ) today announced results from it...ion (NE) drug delivery technology formulated with ...-center, randomized, double-blinded, placebo-contr...he Company,s 3% Diclofenac Diethanolamine NanoEmul...
(Date:11/18/2008)...all/ -- NeuroDiscovery Ltd (ASX:,NDL), a specialt...nt Company,and Sosei Group Corporation ("Sosei";...l biopharmaceutical company, today announce that N...linical efficacy data for NSL-043/SD118.,This inv...pathic pain and has,successfully completed Phase ...
(Date:11/18/2008)...gnosed, elderly AML patients , , PRINCETON,...cals today announced that the first patient has be...of CPX-351 (Cytarabine:Daunorubicin) Liposome Inje...id leukemia (AML). , , The first patient wa...al College of Cornell University and New York Pre...
(Date:11/12/2008)...Watson, Marilyn & James Simons and,Sherry Lansing ... 12 J. Craig Venter,Ph...Institute (JCVI), was,awarded the Double Helix Med...vember 6th at a gala event in New York City., Dr.... Dr. James D.,Watson for making each of their indi...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2ASTRO selects pediatric oncologist as 2008 honorary member 25838 1ASTRO selects pediatric oncologist as 2008 honorary member 25838 2Combination Therapy Helps to Combat Myeloma 25834 1Combination Therapy Helps to Combat Myeloma 25834 2Combination Therapy Helps to Combat Myeloma 25834 3Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York 7358 1Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York 7358 2Iowa State University researcher shows proteins have controlled motions 4624 1Iowa State University researcher shows proteins have controlled motions 4624 2
...g Editor Harvard Medical School ,The FDA ap...can patients has underscored the concept that two ...ation. This concept holds true for a wide variety... to individual genetic variations. As the field of...e new laboratory tools have arrived to help clinic...
...rst human case of West Nile virus (WNV) for 2005 w...e. The CDC has released few details on the patien...nted incidence of the mosquito borne disease in th...lavivirus of about 11 kb. It primarily infects bi... vertebrates serving as incidental hosts. The vir...
Other Medicine Technology:Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 2Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 3West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 2West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 3West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 4
Healon vitreous aspirating cannula, 21 gauge.
Flexible silicone tip cannula allows atraumatic access through retinal tear or hole for aspiration of subretinal fluids. Silicone tube extends 6mm beyond end of cannula. Luer lock hub for easy, sec
Ultra thin wall .90 mm (20 g) cannula allows maximum flow rate, 6 mm in length. Cannula beveled for easy insertion through sclerotomy. 3201 has 16 cm (6 in) high pressure PVC tubing to allow injectio
...ective line of compact CO2 systems combines portab...ature an extremely accurate laser beam, as well as...cially advantageous for small operating theatres a.... Use of special contact tips and accessories allo...
Medicine Products: